UK's Hikma Pharma holds annual outlook, preps for US generic drug tariffs

• Hikma had previously lowered medium-term targets in February due to challenges in one division and U.S. manufacturing delays
• The company positions itself favorably for U.S. supply chain strengthening efforts, with majority of U.S. medicines manufactured domestically in Ohio and New Jersey
• Middle East and North Africa markets account for about one-third of core revenue, making it the second-biggest market after North America

Summary

Company Performance:

Hikma Pharmaceuticals, a UK-based generic drugmaker, reported a 9% increase in half-year core operating profit and maintained its full-year outlook. The company is executing a turnaround strategy focused on expanding its product portfolio and streamlining manufacturing operations.

Strategic Context:

Hikma was forced to revise its medium-term targets in February due to challenges in one division and U.S. manufacturing delays. CEO Said Darwazah highlighted progress on strategic priorities, including new product launches, pipeline strengthening, partnerships, and manufacturing optimization.

Geographic Exposure:

• North America: Largest market; majority of U.S.-sold medicines manufactured domestically in Ohio and New Jersey
• Middle East and North Africa (MENA): Second-largest market, accounting for approximately one-third of core revenue

Tariff Preparations:

The company is positioning itself ahead of potential U.S. tariffs on generic drug imports, which aim to boost domestic manufacturing. Hikma emphasized its strong U.S. manufacturing footprint and stated it will continue constructive engagement with the U.S. administration.

Market Implications:

Hikma's domestic U.S. manufacturing capacity may provide a competitive advantage if generic drug tariffs are implemented, potentially insulating it from import duties affecting competitors. The company's geographic diversification across North America and MENA markets offers revenue stability. The maintained outlook despite previous challenges suggests management confidence in the turnaround strategy's effectiveness.

The report indicates Hikma is proactively addressing both operational challenges and regulatory headwinds while leveraging its U.S. manufacturing presence as a strategic asset.